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Rab33A: Characterization, Expression, and Suppression
by Epigenetic Modification
Elaine Cheng1, Sergio E. Trombetta2, Daniela Kovacs1,7, Robert D. Beech3, Stephan Ariyan4,
Miguel Reyes-Mugica5, Jennifer M. McNiff1,5, Deepak Narayan4, Harriet M. Kluger6, Mauro Picardo7
and Ruth Halaban1
Rab33A, a member of the small GTPase superfamily, is an X-linked gene that is expressed in brain, lymphocytes,
and normal melanocytes, but is downregulated in melanoma cells. We demonstrate that in normal melanocytes
Rab33A colocalizes with melanosomal proteins and that a constitutively active GTPase mutant suppresses their
transport to the melanosomes. In the brain, Rab33A is present throughout the cortex, as well as in the
hippocampal CA fields. A survey of melanocytic lesions demonstrated that aberrant downregulation of Rab33A
is an early event that is already prevalent in melanocytes of giant congenital nevi. Analyses of bisulfite-modified
DNA revealed that Rab33A is regulated by DNA methylation of a specific promoter region proximal to the
transcription initiation site, and that suppression of Rab33A in melanoma cells recapitulates normal processes
that control silencing of X-linked genes, but not tissue specific gene expression. This information is important
for understanding carcinogenesis as well as other aberrant processes because Rab33A may have an important
role in disorders involving X-chromosome-linked genes associated with vesicular transport.
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INTRODUCTION
Genome-wide differential gene expression analyses of
normal human melanocytes as compared to cells isolated
from advanced melanoma lesions have revealed changes that
are likely to influence cellular behavior and be associated
with the malignant phenotype (e.g. see Hoek et al., 2004).
Our previous work demonstrated that several genes
encoding Rab small GTPases were prominently downregu-
lated in melanoma cells compared to normal melanocytes,
including Rab27A, Rab31, Rab32, Rab33A, and Rab38
(Hoek et al., 2004). From this group, Rab33A was chosen
for further analysis because (a) gene transcripts were
uniformly suppressed in the six independent melanoma cell
strains tested (Hoek et al., 2004); (b) the gene is expressed
in a tissue-specific manner, being high in brain, lymphoid
(particularly B lymphoblasts), and monocytic cells and
barely detectable in other tissues (Zheng et al., 1997, 1998;
Su et al., 2004); and (c) the gene is localized in chromosomal
region Xq26.1 and is likely to be subjected to normal
X-inactivation processes. Although the function of Rab33A is
not known, a recent study supports the notion that it
participates in host immune responses because Rab33A is
significantly reduced in CD3-positive lymphocytes in patients
with tuberculosis compared to healthy individuals (Jacobsen
et al., 2005).
Chromosomal modification via DNA methylation is a key
mechanism implicated in tissue-specific gene expression,
X chromosome inactivation, and the suppression of imprinted
genes (Jaenisch and Bird, 2003). Methylation of DNA at the
C-5 position of cytosine (5-methyl cytosine) occurs in the
majority of adult tissues almost exclusively in CpG dinucleo-
tides (Costello and Plass, 2001; Paulsen and Ferguson-Smith,
2001). This dinucleotide is relatively uncommon in most of
the genome (approximately 1 per 50–100 bp, which is one-
third to one-sixth the amount expected randomly), but is
enriched in short stretches of CpG-dense DNA known as
CpG-rich islands that are on average 1–2 kb in length. There
are approximately 30,000 such islands in the sequenced
portion of the human genome, and roughly half of these
islands are thought to overlap promoter regions, because they
surround the 50 ends of genes (Costello and Plass, 2001; Bird,
2002). The presence of methylated cytosines alters the
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Aberrant patterns of DNA methylation are frequent in a
variety of cancers including melanoma (Hoon et al., 2004;
Feinberg and Tycko, 2004; Esteller, 2005a, b). Many genes
associated with tumor suppression, apoptosis, DNA repair,
adhesion, and response to interferon are silenced by this
process in cancer cells (Esteller et al., 1999, 2001, 2002;
Feinberg and Tycko, 2004; Ballestar and Esteller, 2005a, b;
Chen and Baylin, 2005). We therefore surmised that CpG
methylation of the Rab33A promoter might contribute to its
downregulation in melanoma cells.
In this report, we investigated Rab33A cell-specific
expression and its subcellular localization within melano-
cytes and tested its function by ectopic expression of
dominant-negative and dominant-positive mutant proteins.
We then assessed the role of promoter methylation in the
modulation of Rab33A transcription. We demonstrate that (a)
in melanocytes, Rab33A colocalizes with melanosomal
proteins; (b) in mouse brains, it is found in specific regions
associated with memory and cognitive functions; (c) ectopic
expression of a Rab33A mutant with reduced endogenous
GTPase activity attenuated the levels of melanosomal pro-
teins throughout the cell; and (d) downregulation of Rab33A
in melanoma cells is orchestrated by methylation of a specific
CpG island region that also governs this gene’s normal X
chromosome silencing, but not tissue-specific suppression.
RESULTS
Tissue-specific expression and subcellular localization of
Rab33A
The melanocyte-specific expression of Rab33A in skin cells
was demonstrated by reverse transcriptase-PCR (RT-PCR)
analysis of gene transcripts. Rab33A was specifically ex-
pressed in melanocytes (M), but not in keratinocytes (K),
fibroblasts (F), or endothelial cells (E) (Figure 1a).
To examine endogenous and ectopically expressed
proteins, we raised polyclonal antibodies against a peptide
corresponding to an N-terminal sequence unique to Rab33A.
We also subcloned Rab33A from human melanocyte cDNA
and constructed a Flag-tagged Rab33A mammalian expres-
sion vector. The plasmid was transfected into melanoma cells
(501 mel lacking endogenous Rab33A), and the transiently
transfected cells were used to ascertain the specificity of the
anti-Rab33A polyclonal antibodies, and to determine the
subcellular localization of the ectopic protein. Successive
Western blotting with anti-Flag mAb and anti-RAB33A
peptide antibodies confirmed that each recognized a single
band with similar migration pattern, validating the specificity
of the Rab33A antibodies and the integrity of the fusion gene
construct (Figure 1b). Furthermore, the anti-Rab33A
antibodies recognized a single protein band in melanocyte
(M) lysates from normal human (h) and mouse (m) skin
and in mouse brain extract, all displaying a slightly
faster mobility than FlagRab33A, as expected from the
additional Flag epitope (eight amino-acid residues) in
the construct.
Immunostaining of mouse brain with anti-Rab33A anti-
bodies revealed high levels of expression in the cortex and
hippocampus, with lower levels in other brain regions
including the olfactory bulb and cerebellum. Rab33A was
present in the cortex throughout all cellular layers (Figure 1c,
ii–vi). In the hippocampus, expression was seen in the stratum
pyramidale as well as in the adjacent subiculum and some
isolated cells in the hilus of the dentate gyrus stratum (Figure
1d, regions as marked). Rab33A was also expressed in the
glomerular layer of the olfactory bulb (Figure 1e, bracket),
and in the pyramidal cell and granule cell layers of the
cerebellum (Figure 1f).
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Figure 1. Tissue-specific expression and subcellular localization of Rab33A.
(a) The figure shows Rab33A gene transcripts in normal human melanocytes
(M), keratinocytes (K), fibroblasts (F), and endothelial cells (E) compared to
b-actin employing RT-PCR. Rab33A primer pair that amplifies the 835 bp
was employed in this RT-PCR analysis (35 cycles). (b) Western blot analysis
of Rab33A in transfected 501 mel melanoma cells (lanes 1 and 2), normal
human melanocytes (lane 3), normal mouse melanocytes (lane 4), and mouse
brain (lane 5). The membrane was blotted with anti-Flag mAb (Flag) or with
anti-Rab33A antibodies as indicated. (c–f) Expression of Rab33A in the adult
mouse brain. The figure shows parasagittal sections (35 mm) from adult mouse
brain stained with anti-Rab33A peptide antibodies and photographed at
original magnification  20. (c) Cortex. Rab33A is expressed throughout all
cellular layers of the cortex (ii–vi), as well as in the pyramidal cell layer of the
hippocampus below (arrow). (d) Hippocampus. Expression is seen in the
stratum pyramidale as well as in the adjacent subiculum (Sub) and some
isolated cells in the hilus of the dentate gyrus (arrows). SO, stratum oriens;
SP, stratum pyramidale; SR, stratum radiatum, SLM, stratum lacunosum
moleculare; SM, stratum moleculare; SG, stratum granulare. (e) Olfactory
bulb. Expression of Rab33A in the olfactory bulb is highest in the glomerular
layer (GL, bracket). NL, olfactory nerve layer. GCL, granule cell layer.
Panel d scale bar of 500 mm applies to panels c–e. (f) Cerebellum. Expression
is seen in the pyramidal cell layer (PC, arrows) and in the underlying granule
cell layer (Gc). Ml, molecular layer. Bar¼ 250 mm.
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Rab33A colocalizes with melanosomal proteins, and its mutant
form suppresses transport to the melanosomes
Immunofluorescence microscopy of FlagRab33A-transfected
melanoma cells demonstrated that the anti-Flag and
anti-Rab33A antibodies labeled the same intracellular com-
partments in the perinuclear region, dendrites, and dendrite
tips, confirming that the Rab33A peptide antibodies recog-
nized Rab33A (Figure 2a). The endogenous Rab33A in
normal melanocytes was distributed in a similar vesicular
pattern that was also shared by the melanosomal protein
Tyrp1 (Vijayasaradhi et al., 1995; Halaban et al., 2000;
Halaban et al., 2001) and gp100 (Figure 2b and c, yellow
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Figure 2. Subcellular localization of Rab33A, Tyrp1, and gp100 in melanocytic cells. (a–c) Rab33A is localized in vesicular compartments. (a)
Immunofluorescence of FlagRab33A-transfected melanoma cells probed with anti-Rab33A (green), anti-Flag mAb (red), and the merged images (Merge). Cells
were fixed 2 days after transfection. The DAPI-positive cell devoid of any staining (left side of images) represents a cell that is not expressing FlagRab33A and is
also negative for endogenous Rab33A as expected from gene expression analysis and Western blotting. The 10 mm scale bar is for panels a and b. Panels b and c
are immunofluorescence images of normal human melanocytes stained with anti-Rab33A (green), or anti-Tyrp1 mAb TA99 (red) and the merged images
(Merge). The enlarged image of a dendrite in panel c taken by confocal microscopy shows vesicles in which Rab33A colocalizes with Tyrp1 (yellow arrows), and
vesicles in which the two do not share the same compartment (red and green arrows). Bar¼ 10 mm. (d–i) Subcellular localization of wt and mutant FlagRab33A
proteins compared to Tyrp1 and gp100 in transiently (1 day) transfected 501 mel melanoma cells. (d–f) Immunostaining of Tyrp1 (TA99 mAb, red), Rab33A (anti-
peptide polyclonal antibodies, green), and merged image (Merge). Cells were transfected with wt Rab33A (Rab33Awt), mutant Rab33A-Q95L, or mutant
Rab33A-T50N as indicated. (g–i) Immunostaining of gp100 (HMB45 mAb, red), Rab33A (green), and merged images (Merge). The white arrows in panels d–i
point at Rab33A-Q95L- and Rab33A-T50N-expressing cells. In the merged images, yellow arrows indicate colocalized proteins, whereas green and red arrows
point at sites in which Rab33A and melanosomal proteins, respectively, are not in the same compartment. The 10 mm bar in panel d is for all panels in d–i.
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arrows), although the colocalization was not complete
(Figure 2c, red and green arrows).
The effect of Rab33A on Tyrp1 and gp100 was tested by
ectopic expression of gain- and loss-of-function Rab33A
mutants. Constitutively active Rab33A was generated by the
substitution of Gln95 by Leu in FlagRab33A (Rab33A-Q95L),
a mutation in the second motif of the GTP-binding domain
that is expected to decrease GTPase activity as shown for
other Rab proteins (Feig, 1999). On the other hand, inactive
Rab33A was constructed by the substitution of Thr50 by Asn
in FlagRab33A (Rab33A-T50N). This mutation in the first
motif of Rab33A GTP-binding domain is expected to block
the GDP-to-GTP exchange necessary for Rab activation (Feig,
1999). Immunofluorescence analyses of transiently trans-
fected cells revealed that the mutant Rab33A proteins were
distributed throughout the cytoplasm and no longer coloca-
lized with Tyrp1 or gp100 (Figure 2, green fluorescent cells in
panels e and f compared to panel d, and panels h and i
compared to panel g). Furthermore, the levels of Tyrp1 and
gp100 were dramatically decreased in cells expressing high
levels of Rab33A-Q95L relative to untransfected neighboring
cells and wild-type (wt) Rab33A transfectants (Figure 2a and
h, red fluorescent cells marked with white arrows). This effect
was less distinctive in cells expressing low levels of Rab33A-
Q95L (Figure 2h, cell marked with double white arrow). In
contrast, the inactive mutant Rab33A-T50N did not signifi-
cantly disturb the distribution and levels of Tyrp1 and gp100
(Figure 2f and i). These latter results are consistent with the
observation that Tyrp1 and gp100 are normally localized to
melanosomes in cells devoid of Rab33A (such as the 501 mel
cells used for transfection).
Early suppression of Rab33A in melanocytic lesions
As mentioned above, we first discovered the loss of Rab33A
mRNA expression in melanoma cells as compared to normal
melanocytes by using the Affymetrix expression analysis
approach (Hoek et al., 2004). We now examine Rab33A
protein levels by Western blot analysis employing melano-
cytes from benign lesions, short-term cultured melanoma
cells, established melanoma cell strains, and snap-frozen
tumors. The results show that suppression of Rab33A is an
early event in melanocytic lesions. The protein was present in
nevocytes from small nevi (three independent donors) but not
in six out of seven nevocytes from congenital giant nevi
(Figure 3a, compare lanes 3–5 to lanes 6–12). This pattern of
expression/suppression was not related to age or gender, and
suppression was specific to the lesional nevocytes. The levels
of Rab33A were normal in melanocytes from uninvolved skin
of the same patient with giant nevus (Figure 3a, YUYAG,
compare lanes 12 and 13). There was also no relationship
between age and Rab33A suppression. The YUZUV, YUBUR,
YUGIR, YUWAC, YUWAL, and YUYAG non-expressing
nevocytes originated from individuals who were 2.5 years,
11 months, 3, 4, 1, and 34 years old, respectively (lanes 6, 7,
8, 9, 10, and 12), whereas the expressing YUFUR, YUHOB,
YUPAR, and YUOLD nevocytes were from patients 13, 29,
25, and 10 years old, respectively (lanes 3, 4, and 5).
Although all the samples deficient in Rab33A were from
female donors, there were equal numbers of male and female
donors among the expressing group (compare samples from
male donors in lanes 3 and, 11 to samples from female
donors in lanes 4 and 5), suggesting that gender did not play a
role in Rab33A expression. In addition, culture conditions did
not affect expression because all nevocyte samples were
grown in the same medium and tested after one or two
passages in culture. Moreover, one-day incubations of
melanoma cells (1335 mel) in melanocyte medium (TICVA
– medium containing TPA (12-O-tetradecanoyl phorbol-13-
acetate), IBMX (3-isobutyl-1-methyl xanthine), Na3VO4, and
dbcAMP (N6,20-O-dibutyryladenosine 3:5-cyclic monophos-
phate)), or normal melanocytes in melanoma medium did not
change Rab33A mRNA levels in the respective cells (data not
shown).
Rab33A was uniformly downregulated in melanoma cells
and melanoma tumors, confirming our original results based
on mRNA levels (Hoek et al., 2004). Very faint reactive bands
were detected in only three out of 15 melanoma cell strains
and tissue samples tested (Figure 3b, YUDEW, YUFIC, and
1335 mel; data not shown). These observations could not be
expanded to a much larger sample size because attempts to
probe melanoma tissue microarrays with the anti-Rab33A
peptide antibodies failed owing to excessive nonspecific
background.
Rab33A promoter methylation
Four CpG-rich islands are present in the Rab33A proximal
promoter and exon 1 (identified by the web-based MethPrime
program; Figure 4a). The methylation of three of these CpG
islands flanking the initiation start site was assessed by
(combined bisulfite restriction analysis) COBRA, BS-MSP
(bisulfite methylation-specific PCR), and BS sequencing
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Figure 3. Downregulation of Rab33A in giant congenital nevi and
melanomas. (a) Western blot analysis of Rab33A employing cell extracts from
normal melanocytes (NM) isolated from foreskins (NB) and adult female skin
AP48F (lanes 1 and 2, respectively), small nevi (lanes 3–5), congenital giant
nevi (lanes 6–12), and the normal skin of YUYAG adjacent to the giant
nevus (lane 13). (b) Western blot analysis of Rab33A in several metastatic
melanomas (as indicated) compared to normal melanocytes (NM) from adult
skin AP48F. Actin was used as control for protein loading.
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(Herman et al., 1996; Sasaki et al., 2003) as illustrated in
Figure 4a. These procedures take advantage of DNA
sequence differences between methylated and unmethylated
alleles after BS DNA modification, which deaminates
unmethylated cytosine converting it to uracil, but spares
methylated cytosine (Frommer et al., 1992). Therefore, after
PCR amplification, unmethylated DNA molecules will
have an A:T pair instead of C:G, whereas the methylated
(5-methylcytosine) pairs are resistant to this modification and
remain as cytosine (C:G). In COBRA analyses, we used
restriction enzymes such as HhaI, TaqaI, BsiEI, NcoI, or MaeII
that cut unconverted (methylated) but not converted
(unmethylated) DNA to assess methylation.
We first verified that Rab33A is intact in several melanoma
cell strains and tumor samples by amplifying the unmodified
promoter region with wt primers (Figure 4b). In addition, we
confirmed that the DNA was completely modified by the BS
treatment by demonstrating that amplified wt non-converted
but not BS converted DNA was digested by DraII, a restriction
enzyme that targets GG/GTCCT sites (Figure 4c). The
methylation status of the BS converted DNA was also
confirmed by digesting the gel purified MSP fragments with
NcoI. This enzyme digests the non-CpG segment C/CATTGG
in the unconverted DNA generating 133 and 72 bp fragments,
whereas the converted (TTATGG) DNA remains intact. There
were no fragments after digestion of several samples from
melanoma cells, indicating complete BS conversion of DNA
(data not shown). The methylation analyses described below
showed that, among the three CpG islands, CpG island 2 was
critical for Rab33A expression.
Analysis of CpG islands 1 and 3. COBRA analysis ruled out
methylation of CpG1 and CpG3 as the basis for suppression
of gene expression. The X-inactive chromosome was not
methylated in this region because CpG1 was resistant to HhaI
digestion regardless of gender (Figure 5a, compare NM lanes
1 and 2). In addition, this region was not methylated in
expressing YUOLD nevocytes and non-expressing YUDEW
melanoma cells (resistant to HhaI digestion). CpG1 was
completely methylated only in the YUMAC melanoma cell
strain (Figure 5a, and confirmed by BS sequencing, Figure
S1). Age did not play a role in the methylation pattern
because the two non-expressing melanoma cell strains
YUDEW and YUMAC originated from 68-year-old patients
(Table 1).
Methylation analysis of fresh newborn skin, and formalin-
fixed paraffin-embedded nevi and melanoma lesions, all
derived from male individuals, showed again that CpG1
methylation did not correlate with the malignant state. TaqaI
and HhaI digestion products were present in the two small
nevi YDP96 and YDP44, and two of the three melanoma
lesions analyzed (Figure 5b, compare YDP05 and YDP50 to
YDP60).
The region analyzed in CpG3 (Figure 6a) was composed of
methylated and unmethylated alleles regardless of gender or
Rab33A expression (Figure 6b, compare expressing AP48F
normal melanocytes to non-expressing YUDEW melanoma
cells). The mixture of alleles indicates variations within the
cell population. BS sequencing also showed that CpG3 was
highly methylated in normal melanocytes, nevocytes
(YUOLD and YUYAG), snap-frozen melanoma tumor (YU-
PEF), and WW165 primary melanoma cells. Low levels of
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Figure 4. Rab33A promoter is intact and undergoes complete BS modifica-
tion. (a) Schematic representation of Rab33A promoter region and first exon.
The genomic structure of Rab33A is based on Rab33A mRNA sequence
(Accession no. NM_004794) and human DNA sequence from clone
RP3-438D16 on chromosome Xq24-26.1, accession number AL139234. The
horizontal line indicates the promoter region and the first exon (box). The
vertical arrow marks the ATG open reading frame site of Rab33A, the multiple
short bars above the line are sites of CpG dinucleotides, and gray boxes CpG
islands 1–3 (identified by the MethPrime program). The scale below the line
represents bp. The arrows indicate the amplification sites of Rab33A
unmodified (wt) DNA. The bracketed bars delineate the regions amplified
with BS primers and analyzed for DNA methylation. All primers are listed in
Table 2. (b) Rab33A promoter is intact in melanoma cells. Unmodified
Rab33A promoter from normal melanocytes (NM), cultured melanoma cell
strains MNT1, WW165, YUMAC, YUSIT1, and 501 mel, and melanoma
tumors YUGUL, YUPEF, YUSOM, and YUWAK (see Table 1 for more details)
was amplified by employing Rab33A wt primers (Table 2). Reaction products
were separated in agarose gel and visualized under UV light. (c) Validation of
BS modification. Non-converted DNA from the YUMAC melanoma was
amplified with wt primers (Rab33Awt), and BS-converted DNA samples from
normal melanocytes (NM) and YUMAC melanoma cells were amplified first
with BS1 primer pairs that bind modified DNA in a non-CpG region. A
portion of the amplified and purified 263 bp fragments (1/20th) was then
subjected to a second round of amplification (35 cycles) with nested MSP
primers that recognize either methylated (m) or unmethylated (u) DNA
(Table 2, M1 and U1 primers), generating products of 182 and 186 bp,
respectively (BS-MSP). Half of the reaction products were kept as control
(–), whereas the other half were digested with DraII restriction enzyme
(þ ) that cuts the sequence GG/GTCCT in a non-CpG dinucleotide segment.
Products were separated in 1% agarose gel and visualized under UVB light.
The results show that DraII digested the 265-bp wt DNA to two fragments of
155 and 110 bp but not the methylated and unmethylated 182 and 186 bp
fragments, respectively, which were otherwise expected to generate 124 and
53 bp fragments, indicating complete conversion by BS.
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unmethylated alleles (TG instead of CG) were also detected at
equal levels in expressing and non-expressing cells (Figure
6c, compare YUOLD expressing to YUYAG non-expressing
nevocytes). Although this region was completely methylated
in WW165 melanoma cells, low levels of the unmethylated
allele were present in YUPEF tumor almost to the same extent
as in nevus cells (YUOLD and YUYAG) (Figure 6c),
suggesting that modification of CpG3 is not involved in
malignant progression.
CpG islands 2. COBRA, BS-MSP, and BS-sequencing analyses
suggested that methylation of CpG2 silences Rab33A expres-
sion on the inactive X chromosome and on the functional X
chromosome in non-expressing melanoma cells.
COBRA analysis showed that this region (Figure 7a)
displayed different methylation patterns between male and
female donors. Only the unmethylated allele was detected in
foreskin melanocyte because the amplified fragment from BS-
modified DNA was resistant to digestion by TaqaI restriction
enzyme. In contrast, the unmethylated and methylated alleles
were present in melanocytes from a female donor because
TaqaI-resistant and -sensitive fragments were present
(Figure 7b, NM and YUMURJ). The predominant presence
of the unmethylated CpG2 allele in expressing melanocytes
was further confirmed by BS-MSP analysis (Figure 7d, NM),
and BS sequencing (Figure 8, YUOLD, gray boxes).
Inactivation of Rab33A in lesional melanocytes was
associated with CpG2 methylation on the functional X
chromosome. All amplified BS-modified DNA samples from
primary and metastatic melanoma lesions were completely
digested by TaqaI to the expected size fragments of 113 bp
(Figure 7b). COBRA analysis with HhaI and MaeII restriction
enzymes provided further evidence that additional CpG
dinucleotide pairs were methylated (sensitive) in YUMAC
melanoma, but unmethylated (resistant) in normal melano-
cytes (Figure 7c). Furthermore, BS-MSP analysis showed high
levels of methylated CpG2 alleles in the non-expressing
congenital giant nevocytes YUZUV and YUBUR, as well as
the early primary melanomas WW157, WW88, WW94, and
a recurrent melanoma YUCOR (Figure 7d), and predomi-
nantly the methylated CpG2 allele in advanced melanomas
derived from cultured cells and snap-frozen specimens
(Figure 7e and f, respectively). Finally, BS sequencing showed
that the methylated allele was predominant in primary
melanoma WW165, and metastatic melanoma YUGUL and
YUMAC cells (Figure 8, black boxes). These differences in the
pattern of methylation did not reflect the age or gender of the
donors, because the nevi were from infants and there were
equal representations of male and female donors (Table 1).
CpG2 methylation analysis of DNA from freshly excised
newborn foreskins shows a predominance of methylated over
unmethylated Rab33A CpG2 forms (Figure 7e, skin).
Although this pattern can be expected in a tissue in which
the melanocytes are in the minority, as will be seen later
(Figure 10), CpG2 is also not methylated in undifferentiated
cultured keratinocytes.
Taken together, these data indicate that DNA methylation
in CpG2, a region located þ98 to þ141 base pairs down-
stream of the transcription initiation site, is an aberrant early
event in the melanocytic cellular system, occurring in giant
nevi that do not express Rab33A and persisting in primary
and metastatic melanoma cells and tumors.
Restoration of Rab33A gene expression
Some genes silenced by chromatin modification can be
reactivated by the demethylating agent 5-Aza-20-deoxy-
cytidine (5-Aza-CdR) (see e.g. Hoon et al., 2004). We
therefore explored the effect of 5-Aza-CdR on Rab33A
expression and promoter demethylation in melanoma cells.
Figure 9 shows that short-term exposure (2 days) to low
concentrations of the drug (0.1mM) was effective in restoring
Rab33A mRNA expression (Figure 9a) and the demethylated
state of some cytosine residues of the Rab33A promoter
(Figure 9b, arrows).
Cell-specific Rab33A suppression is not determined
by promoter methylation
The results so far suggest that inactivation of Rab33A in
melanocytic lesions recapitulated X-chromosomal-silencing
process. We therefore further explored whether cell-type-
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(b) BS-treated DNA from normal human melanocytes (NM), newborn skin
(Skin), formalin-fixed and paraffin-embedded nevi (YDP96 and YDP44), and
primary melanoma lesions (YDP05, YDP 60, YDP50) were processed and
digested with TaqaI or HhaI restriction enzymes (lanes marked with þ ) as in
a, except that reaction products were separated in 1% agarose gel.
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specific expression in cultured skin cells is also controlled by
CpG promoter methylation. COBRA and BS-sequencing
analyses revealed that the unmethylated CpG1 and CpG2
alleles were predominant in keratinocytes and fibroblasts
isolated from newborn foreskins in a manner similar to
normal melanocytes (Figure 10). These results demonstrated
that cell-specific expression is controlled by processes that do
not include methylation of Rab33A promoter.
Table 1. Melanocytic lesions and short-term cultured cells
Specimen Gender/age (years) Lesion
(a) Nevus cells in culture
YUFUR M/13 Intradermal nevus 0.80.5 cm
YUPAR F/25 Intradermal nevus 0.50.5 cm
YUHOB F/29 Congenital nevus 4.53.8 cm
YUBUR F/1 Giant congenital nevus
YUWAL F/1 Giant congenital nevus
YUZUV F/2.5 Giant congenital nevus
YUGIR F/3 Giant congenital nevus, neurocutaneous melanosis
YUWAC F/4 Giant congenital nevus
YUOLD M/10 Giant congenital nevus
YUYAG M/34 Giant congenital nevus
(b) Snap-frozen nevus
YUMURJ F/17 Blue nevus
(c) Formalin-fixed paraffin-embedded nevi
YDP96 M/60 Intradermal melanocytic nevus (1.21.0 0.6 cm)
YDP44 M50 Intradermal melanocytic nevus (1.30.9 0.5 cm)
(d) Primary melanoma cells
WW165 F/62 Primary melanoma (2.25 mm)
WW157 M/86 Melanoma in situ
WW88 F/71 Superficial spreading invasive melanoma (0.2 mm)
WW94 M/43 Primary melanoma (1.45 mm)
(e) Formalin-fixed paraffin-embedded primary melanomas
YDP72 M/49 Nodular melanoma (19.0 mm)
YDP05 M/70 Superficial spreading melanoma (4.6 mm)
YDP60 M/28 Superficial spreading melanoma (4.5 mm)
YDP50 M/49 Nodular melanoma (8.7 mm)
(f) Advanced melanoma cells
YUDAN F/44 Lymph node metastasis
YUGEN8 F/44 Brain metastasis
YUCOR F/30 Recurrent melanoma adjacent to the primary lesion
MNT1 M/60 Lymph node metastasis
YUMAC M/68 Soft tissue metastasis
YUDEW F/68 Distant metastasis
YUCINJ F/20 Distant metastasis
YUFIC M/68 Lymph node metastasis
YULYU M/71 Distant metastasis
1335 mel M/47 Lymph node metastasis
YUSIT1 M/67 Metastatic melanoma
(g) Snap-frozen advanced melanoma tumors
YUGUL M/57 Lymph node metastasis
YUPEF M/61 Soft tissue metastasis
YUSOM M/58 Massive recurrent metastasis
YUWAK M/56 Local skin metastasis
M, male; F, female.
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DISCUSSION
This report demonstrates that Rab33A was present in
melanocytes in vesicles occupied by melanosomal proteins
critical for pigmentation. The normal distribution of Tyrp1
and gp100 in Rab33A-null melanoma cells, the normal
pigmentation of nevus cells lacking Rab33A (e.g. YUZUV
and YUYAG), and the lack of significant effect on these
proteins in response to overexpression of the inactive mutant
Rab33A-T50N, indicate that Rab33A is not necessary for the
transport of melanosomal proteins to the melanosomes. On
the other hand, the constitutively active mutant Rab33A-
Q95L suppressed the levels of Tyrp1 and gp100 in a dose-
dependent manner, suggesting interference with intracellular
vesicular transport. The GTP-bound forms of Rab proteins
display high affinity for other proteins, such as tethering
factors, which in turn complex with SNARE proteins
(reviewed by Novick and Zerial, 1997; Deneka et al.,
2003). We surmise that Rab33A-Q95L, which was misloca-
lized in the cytosol, may trap essential ‘‘effectors’’, depleting
their supply in the vesicular system for other Rab proteins and
impairing critical steps required for the transport of Tyrp1 and
gp100 to the melanosomes.
It is estimated that the human genome contains at least 60
Rab family members (Stenmark and Olkkonen, 2001). Among
those affecting normal pigmentation are Rab27A and Rab38
(reviewed by Seabra and Coudrier, 2004). Mutations in
Rab27A impede the transport of subcellular organelles to the
periphery, including melanosomes as well as cytotoxic
granule transport, causing depigmentation, immune defi-
ciency, and blood disorders. Rab27A mutation is associated
with Griscelli syndrome type 2, characterized by partial
albinism and uncontrolled T-lymphocyte and macrophage
activation (reviewed by Seabra and Coudrier, 2004). On the
other hand, abnormality in Rab38 is implicated in the
pathogenesis of Hermansky–Pudlak syndrome, an autosomal
recessive disorder characterized by albinism and prolonged
bleeding (reviewed by Di Pietro and Dell’Angelica, 2005).
Rab38 is an endoplasmic reticulum resident protein, and is
likely to be responsible to the transport of melanosomal
proteins to the Golgi compartment (Osanai et al., 2005). We
therefore hypothesize that Rab33A-Q95L disables Rab38 by
depriving it from effector proteins. Consequently, the
melanosomal proteins are detained in the endoplasmic
reticulum and undergo degradation as has been reported for
tyrosinase (Halaban et al., 2000, 2001, 2002).
Probing mouse brain sections with Rab33A-specific
antibodies indicated expression in the cortex as well as in
the hippocampus, regions associated with memory and
cognitive functions. The activity of small GTPases of the
Rho family is critical for proper brain function because
mutations in several genes whose protein products affect this
pathway, GDI1 (GDP dissociation inhibitor 1), PHN1
(Oligophrenin-1), PAK3 (p21 (CDKN1A)-activated kinase 3),
and ARHGEF6 (Rac/Cdc42 guanine nucleotide exchange
factor 6), have already been implicated in X-linked forms of
mental retardation (D’Adamo et al., 1998; Berrettini, 2000;
Kutsche et al., 2000; Raymond, 2005). In rodents, mutation in
Rab23, a negative regulator of the hedgehog signaling
pathway, leads to the mouse open brain phenotype (Evans
et al., 2005). Rab23 is highly homologous to human Rab33A
(Guo et al., 2006). It is thus tempting to speculate that
mutations in Rab33A may also be involved in yet unidentified
X-linked disorders (particularly Xq26–q27) associated with
vesicular trafficking in neurons.
In this report, we also show that silencing Rab33A was an
early event in the transition from benign to abnormal growth
because Rab33A was expressed in melanocytes from normal
skin and small nevi, but not in those derived from congenital
giant nevi (six out of seven specimen), lesions with
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abnormally increased proliferative potential. Furthermore,
suppression of Rab33A was prevalent in melanoma cells
isolated from primary and advanced lesions. Only extremely
low levels of protein were detected in three out of 15 cell
strains or freshly excised snap-frozen tumors. Therefore,
Rab33A may have other functions that can affect cell
proliferation. Overexpression of selected Rab GTPases has
been tightly correlated with the pathogenesis of different
diseases including cancer (reviewed by Stein et al., 2003). For
example, overactivity of Rab25 GTPase enhances the
aggressiveness of ovarian and breast cancers (Cheng et al.,
2004, 2005).
We identified CpG2, located þ 98 to þ141 bp down-
stream of the transcription initiation site, as the region critical
for Rab33A expression. CpG2 was methylated in the silenced
X chromosome, suggesting involvement in X-inactivation
processes. Among the giant nevi, CpG2 was highly methyl-
ated also on the functional X chromosome in the non-
expressing YUZUV and YUBUR, but remained unmethylated
in the expressing YUOLD melanocytes, supporting our notion
that this epigenetic modification is associated with early
aberrant growth processes. CpG2 was also highly methylated
in one primary melanoma dissected from a paraffin-
embedded block (YDP72), five short-term cultures of primary
melanomas (WW88, WW94, WW157, YUCOR), an estab-
lished primary melanoma cell strain from an advanced lesion
(WW165), six strains of metastatic melanomas (YUMAC,
MNT1, YUSIT1, 501 mel, YUDAN, and YUGEN8), and four
snap-frozen melanoma tumors (YUGUL, YUPEF, YUSOM,
and YUWAK). Restoration of Rab33A expression in response
to low concentrations of the demethylation drug 5-Aza-CdR
provided the evidence that this epigenetic modification is an
important process in Rab33A suppression. The results
showed that Rab33A methylation and gene silencing were
common in melanocytic lesions, and may be a useful marker
for early transition to an aberrant mode of growth.
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However, although CpG2 methylation was clearly asso-
ciated with an inactive gene, the presence of the unmethyl-
ated allele was not sufficient to sustain Rab33A expression,
because CpG2 was also not methylated in the non-expressing
fibroblasts and keratinocytes. Interestingly, in whole skin, the
Rab33A promoter was mostly methylated, suggesting differ-
ences between the stratified and proliferative epidermal
layers. Cultured keratinocytes, such as those used in our
experiments, are non-differentiated highly proliferating cells,
whereas most of the keratinocytes in the skin are from the
well-differentiated and stratified epidermal layer. Recent
observations revealed differences in the expression of clusters
of genes in native skin, cultured keratinocytes, and fibroblasts
depending on the proliferative and differentiative state of
these cells (Smiley et al., 2005). Therefore, it is conceivable
that some of these changes in gene expression may be the
results of differences in DNA methylation.
Epigenetic modification is now widely recognized as one
of the critical changes related to malignant transformation.
Chromatin modification, in particular promoter methylation,
is a highly valuable cancer biomarker because (a) DNA is
stable, (b) the change is permanent, and (c) the procedure
involves PCR amplification, and thus requires minute
amounts of material, a limiting factor especially in the case
of melanoma. In addition, the role of chromatin structure in
carcinogenesis has made it a target for the treatment of
malignancy (La Thangue, 2004; Mei et al., 2004; Esteller,
2005a, b; Hess-Stumpp, 2005). Several tumor-related genes
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are downregulated by promoter methylation in cancer cells,
including melanoma. However, in most cases, the frequency
of methylation varies, and no single gene so far has been
identified as methylated in all melanoma tumors (Hoon et al.,
2004; van Doorn et al., 2005). This situation may change, as
more information from genome-wide studies will become
available.
Abnormal expression of several X-linked genes has been
documented in melanomas and other cancer cells. The best-
known example is the MAGE gene family members located
on Xq28 (Hoek et al., 2004 and references within). We
showed that FGF13 that maps to chromosomal region
Xq26.3, and is coordinately differentially expressed with
MAGE genes in the different melanoma cell strains (Hoek
et al., 2004), suggesting aberrant activation of a potent
growth factor by demethylation (Xiao et al., 2005). It is thus
possible that genes located on the X chromosome may be
more susceptible to deregulation by epigenetic modification
that can have an impact on malignant transformation and
tumor progression.
MATERIALS AND METHODS
Cells and tissue samples
Normal cells. Normal human melanocytes, keratinocytes, fibro-
blasts, and endothelial cells were obtained from the Cell Culture
Facility of the Yale Skin Disease Research Core Center (YSDRCC).
Newborn melanocytes, keratinocytes, and fibroblasts were isolated
from discarded foreskins. Adult melanocytes were isolated from the
discarded skin obtained after voluntary abdominoplasty surgery of
a 48-year-old female donor (AP48F). The human dermal micro-
vascular endothelial cells were from normal adult single donor
breast skin (passages 1 and 2) and were used for all experiments.
The normal human melanocytes were cultured in basal medium
(Ham’s F12 medium supplemented with 7% fetal calf serum and
penicillin/streptocmycin) enriched with ingredients required for
proliferation: TPA (50 nM, 12-O-tetradecanoyl phorbol-13-acetate),
IBMX (0.1 mM, 3-isobutyl-1-methyl xanthin), Na3VO4 (1mM), and
dbcAMP (0.1 mM, N6,20-O-dibutyryladenosine 3:5-cyclic monophos-
phate), termed TICVA (Halaban, 2000). Keratinocytes were grown in
KGM-2 medium (Clonetics, Division of BioWhittaker, Walkersville,
MD) supplemented with calcium-depleted serum and the specific
growth factors required for normal human keratinocytes supplied by
Clonetics. Fibroblasts were cultured in the basal Ham’s F12 medium,
and endothelial cells in human dermal microvascular endothelial
cell medium (EGM2-MV from BioWhittaker Cell Biology Products,
Walkersville, MD), supplemented with 5% fetal calf serum plus a
mixture of hydrocortisone, vascular endothelial growth factor, long
recombinant 3-insulin-like growth factor-1, ascorbic acid, heparin,
human recombinant epidermal growth factor, and gentamicin/
amphotericin B.
Benign and malignant melanocytic lesions. We used a panel of
cultured nevocytes, primary and metastatic melanoma cells, as well
as snap-frozen and formalin-fixed paraffin-embedded tissues
(Table 1). The study was conducted according to the Declaration
of Helsinki Principles. Tissue samples were collected according to
Health Insurance Portability and Accountability Act (HIPAA)
regulations with Human Investigative Committee protocol. All
lesional material was excised for the benefit of the patients, and
only excess material was used without jeopardizing diagnosis or
future treatment. Participants gave their written informed consent.
The medical ethical committee of Yale University approved all
described studies. The nevocytes from congenital giant nevi and a
blue nevus and some of the primary melanoma cells (WW88 and
WW94) were grown in the same growth factor-supplemented
medium TICVA used for normal human melanocytes. The WW165
primary melanoma cells were grown with IBMX. The melanoma
cells from metastatic lesions (YUMAC, YUDEW, and YUGUL) were
grown in the basal Ham’s F12 medium. Cells with the YU prefix,
except for YUGEN8 and YUSIT1, were from short-term cultures
(about 1 month) harvested during the first or second passage in
culture. The melanoma cell strains 501 mel, 888 mel, 1241 mel, and
1335 mel were established in the Surgery Branch, National Cancer
Institute, Bethesda, MD, and were maintained in OptiMEM medium
supplemented with antibiotics and 7% fetal calf serum.
Rab33A peptide antiserum
Polyclonal antibodies to the peptide MAQPILGHGSLQPASAAGLA
SLELDSSLDQYVQIR spanning the Rab33A N-terminus domain
(synthesized by Yale Keck Foundation Biotechnology Laboratory,
conjugated to KLH) were raised in rabbits by Cocalico Biological
Inc., Reamstown, PA. Antiserum from one rabbit was determined to
have a high titer when tested against a decreasing concentration of
the peptide blotted on a polyvinyldine difluoride membrane (data
not shown). The antiserum was partially purified with the Melon Gel
Spin purification kit (Pierce, Rockford, IL) before use. This method
was used because any attempts to purify the antibodies by
immunoaffinity employing immobilized synthetic peptide or Protein
A affinity column destroyed the specificity of the antibodies in
response to low pH elution.
FlagRab33A constructs, transfection, expression,
and subcellular localization
Rab33A (accession number NM_004794) was amplified from cDNA
of normal human melanocytes employing 50 oligonucleotide primers
flanked with HindIII restriction site and the FLAG peptide
TAAGCTTACCATGGACTACAAAGACGATGACGACAAGGCGCAG
CCCATCCTGGGC (HindIII site underlined, the Flag encoding
MDYKDDDDK in bold, and Rab33A sequences in italic) and 30
oligonucleotide primers flanked with EcoRV digestion sites
TTTTATTTTGATATCAATTTGTATGGAAAC (EcoRV site underlined,
and Rab33A in italic), annealing temperature 551C and subcloned
into HindIII/EcoRV restriction sites of pcDNA 3.1. Rab33A-Q95L
and Rab33A-T50N mutants were obtained by site-directed mutagen-
esis of the original FlagRab33A plasmid (QuikChange kit; Stratagene,
La Jolla, CA). The fidelity of the constructs was verified by
sequencing the inserts. Purified plasmid DNAs were then transfected
into human melanoma cells (501 mel) employing the Lipofectamine
2000 reagent (Invitrogen Life Technologies, Carlsbad, CA) following
the manufacturer’s instructions. The expression of FlagRab33A
protein was assessed by Western blotting 2 days post-transfection.
Western blotting
Cell pellets were washed in phosphate-buffered saline and lysed in
RIPA buffer (PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS) supplemented with a cocktail of protease inhibitors
www.jidonline.org 2267
E Cheng et al.
Tissue Expression and Suppression of Rab33A
(‘‘Complete’’ Boehringer Mannheim Corp., Roche Molecular Bio-
chemicals, Indianapolis, IN) with slight sonication. Total cell extracts
(35 mg proteins/lane), measured by the Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, CA), were prepared in samples
buffer, heated to 951C for 5 minutes, slightly sonicated for the second
time, centrifuged to remove particulate material, fractionated in 8%
polyacrylamide pre-cast gels (NuPAGE Bis-Tris, NOVEX, San Diego,
CA), and transferred to a polyvinyldine difluoride membrane. The
membrane was first probed with anti-Flag M2 mAb (Sigma-Aldrich,
St Louis, MO) to detect ectopic protein followed by Rab33A
polyclonal antibodies according to standard protocols. The expres-
sion level of endogenous protein was assessed by Western blot
analysis of normal human melanocytes, melanoma cells, and freshly
frozen melanoma tumor lysates with anti-Rab33A antibodies
employing the same procedure.
Immunostaining
Cells. For subcellular localization, cells were grown on coverslips
and processed for immunofluorescence analysis with anti-Flag (M2
mAb, Sigma-Aldrich), anti-Rab33A peptide antibodies, anti-Tyrp1
(mAb TA99) (Vijayasaradhi et al., 1991) or anti-gp100 (HMB45
mAb, DAKO Corporation, Carpinteria, CA) as described by Halaban
et al. (2002). Coverslips were mounted with ProLong Gold anti-fade
reagent with 40,6-diamidino-2-phenylindole dihydrochloride (Mole-
cular Probes, Invitrogen Corporation, Carlsbad, CA) to visualize
nuclear DNA.
Mouse brain. All procedures involving animals were performed in
strict accordance with the National Institutes of Health (NIH)
Guidelines for the Care and Use of Laboratory Animals and were
approved by the Yale Animal Care and Use Committee. Mice were
anesthetized with chloral hydrate and perfused transcardially with
4% paraformaldehyde. Brains were dissected, post-fixed for 48 hours
in 4% paraformaldehyde, cryoprotected in 30% sucrose, and cut
into serial 35-mm parasagittal sections on a freezing microtome. Free
floating sections were washed three times in potassium phosphate-
buffered saline (KPBS), blocked in KPBSþ 0.3% Triton X-100þ 4%
normal serum, and incubated in anti-Rab33A antibodies at a 1:200
dilution overnight at 41C. The following day, sections were washed
three times in KPBSþ 0.3% Triton X-100. After the washes,
secondary antibodies (Alexa-568 anti-rabbit IgG; Molecular Probes,
Eugene, OR) were added at a dilution of 1:2,000 for 1 hour at room
temperature. The sections were washed three times in KPBSþ 0.3%
Triton X-100, twice in KPBS alone, and then incubated for 5 minutes
in 0.7% Sudan Black B/70% methanol to quench autofluorescence.
Sections were washed again and mounted onto positively charged
slides in aqueous anti-fade mounting media (Biomeda, Foster City,
CA). Photomicrographs were taken using a Zeiss Axioscope II
microscope with  63 objective. Images were processed using
Adobe PhotoShop 7.0 (Adobe Systems, San Jose, CA) and Corel
Draw 12.0 (Corel, Ottawa, ON, Canada). Images were adjusted for
contrast and brightness to equilibrate light levels, and were cropped,
resized, and rotated for purposes of presentation. In no case was the
content of images altered.
Rab33A expression
High-quality total RNA was prepared from cell pellets with the
TRIzol reagent (Invitrogen Life Technologies, Invitrogen Corporation,
Carlsbad, CA). Poly(A) mRNA was isolated from total RNA employ-
ing the PolyATtract mRNA isolation system IV (Promega, Madison,
WI) following the manufacturer’s instructions. This additional step is
required because melanin in total RNA suppresses PCR reactions.
cDNA templates were generated from the Poly(A) selected RNAs
using Invitrogen SuperScript II Reverse Transcriptase according to
the manufacturer’s instructions. The levels of Rab33A gene
transcripts were assessed by RT-PCR employing the same primers
used for cloning of Rab33A (see above, products size 835 bp), or
with forward 50-TCCCAGACAAGACTGAAGCCAC-30 and backward
50-GTTGCCCACAAGCACTTTGG-30 primer pairs, annealing tem-
perature 57.11C, 35 cycles, product size 272 bp. As a control,
expression of b-actin was assessed using forward 50-GTGGG
GCGCCCCAGGCACCA-30 and backward primers 50-CTCCTTAAT
GTCACGGCACGATTTC-30, annealing temperature 551C, 35 cycles,
product size 540 bp. All oligonucleotides were synthesized by the
oligonucleotide synthesis facility at the Department of Pathology,
Yale University School of Medicine.
DNA extraction
Cells and snap-frozen tissues. The DNeasy purification kit
(Qiagen Inc., Valencia, CA) was used to extract the DNA from cell
pellets and freshly frozen tumors.
Formalin-fixed paraffin-embedded material. The lesional sites
in the formalin-fixed paraffin-embedded material were marked by a
certified pathologist (J.M.), and 2 mm punch biopsy specimens were
incubated in 300ml DNA extraction buffer at 1001C for 1 hour to
dissolve the paraffin. The samples were then digested with
proteinase K overnight at 601C, and DNA was purified by extraction
with a phenol/chloroform solution. The quality of the DNA was
analyzed by gel fractionation and UV light visualization.
Analyses of Rab33A proximal promoter methylation
Primer design (Table 2) was based on human DNA sequence from
clone RP3-438D16 on chromosome Xq24–26.1 (Accession no.
AL139234) employing the web-based MethPrimer program for
designing BS conversion-based Methylation PCR Primers (Li and
Dahiya, 2002) at http://www.urogene.org/methprimer/index1.html.
Primers that amplify the unmodified promoter region were used to
demonstrate that this region is intact in various melanoma cell strains
and tumors. All methylation analyses were performed on samples
that originated from male individuals in order to avoid contribution
from the female X-inactivated chromosome.
Genomic DNA was isolated and a total of 2 mg was modified by
sodium BS. Reactions were hot started at 941C for 5 minutes after
which 1 U of Platinum Taq polymerase (Invitrogen Life Techno-
logies, Invitrogen Corporation, Carlsbad, CA) was added followed by
35–40 cycles of 941C for 30 seconds, optimal annealing temperature
(Table 2) for 30 seconds, extension at 721C for 30 seconds, and
finally 5 minutes at 721C. PCR reaction products were loaded onto
1% agarose gel, stained with ethidium bromide, and visualized
under UV illumination.
For COBRA analysis, the DNA was amplified with primers that
bind to the BS-treated DNA in non-CpG regions in the converted
DNA (Table 2), and the amplified products (35–40 cycles) were gel
purified. The restriction enzymes used for further analyses were
HhaI, Taqa1, BsiE1, NcoI (New England Biolabs, Hanover, MD) and
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MaeII (Roche Molecular Biochemicals, Indianapolis, IN), which cut
unconverted (methylated) but not converted (unmethylated) DNA.
Digestion was stopped with 1 ml of 1% SDS for 10 minutes at 651C,
to prevent band-shift in polyacrylamide gel owing to binding of
protein to DNA. For BS-MSP, the amplified region was subjected to a
second PCR amplification with internal primers that are methylation
specific (Table 2). For MSP analysis, PCR amplification was
performed directly with primers that selectively bind to converted
(unmethylated) or non-converted (methylated) sequences. For BS-
sequencing analysis, PCR was performed using the same BS primers
described above for COBRA (Table 2), PCR products were gel
purified and the fragments were sequenced by Applied Biosystems
3730 capillary instruments at the W.M. Keck Foundation Biotech-
nology Resource Laboratory at Yale, employing fluorescence-
labeled dideoxynucleotides.
MSP and BS-MSP products were loaded onto 1% agarose gels,
stained with ethidium bromide, and visualized under UV illumina-
tion. In most cases, COBRA amplification products were fractionated
in non-denaturing 8% polyacrylamide gels, stained with ethidium
bromide, and visualized under UV illumination.
Effects of 5-Aza-CdR on gene regulation and DNA methylation
5-Aza-CdR (Sigma Chemical Co., St Louis, MO) was dissolved in
methanol as 10 mM stock solution, aliquoted, and kept at 201C.
Sparse cultures of proliferating melanoma cells were grown in
regular Ham’s F10 medium (control) or in medium supplemented
with 0.1 or 0.2 mM final concentration of 5-Aza-CdR for 2 days, with
fresh drug-containing medium being added on the second day. This
concentration was chosen to avoid cytotoxicity because dose-
response analyses employing several melanoma cell strains showed
that melanoma cells are highly sensitive and stop proliferating when
incubated with 0.5 mM or higher concentrations of 5-Aza-CdR (data
not shown). The cells were then released into regular medium,
allowed to recover for additional 2 days, harvested, and the levels of
Rab33A gene transcripts were assessed by RT-PCR employing
Rab33A-specific primer set 2 (Table 2). In addition, genomic DNA
was collected to identify changes in Rab33A promoter methylation
in response to 5-Aza-CdR.
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SUPPLEMENTARY MATERIAL
Figure S1. CpG1 BS-sequence analysis.
Table 2. Oligonucleotide primers for amplification of Rab33A promoter
Application Relative to TS Designation Primers Tan (1C) Product size (nt)
PCR wt 231 to 208 WTF 50-GGCAAGGAGAAAGAAGTCTATCCC-30 61.4 265
+33 to +14 WTB 50-CGGAGGCACCAACACAAAAG-30
CpG island 1
COBRA 233 to 209 BS1F 50-GGGGTAAGGAGAAAGAAGTTTATTT-30 52.9 263
+29 to +4 BS1B 50-AACACCAACACAAAAACCAAAA-30
Nested for BS sequencing BS1Ba 50-CCAAAAAAAAAAAAAAAAAAAAAAAAAAAT-30 247
MSP1 nested 232 to 208 M1F F: 50- GGGTAAGGAGAAAGAAGTTTATTTC -30 53.3 182
51 to 72 M1B B: 50-TCGAACCGAATACTCTAACGAA-30
233 to 216 U1F F: 50-GGGGTAAGGAGAAAGAAGTTTATTT-30 51.8 186
48 to 82 U1B B: 50-CCCTCAAACCAAATACTCTAACAAA -30
CpG island 2
BS2 +75 to +96 BS2F 50-GGAGTGAGAGGTATTTTTTTTA-30 51.9 226
+300 to +270 BS2B 50-ACTACAAACTCCCATAACCCAAA-30
MSP2 +152 to +179 M2F 50-CGCGCGTATATATATACGTATAGAGTTC-30 53.3 205
+356 to +335 M2B 50-GTACTAATCCAACGACGAATCG-30
+151 to +180 U2F 50-ATGTGTGTATATATATATGTATAGAGTTTG-30 55.4 211
+361 to +335 U2B 50-TACACATACTAATCCAACAACAAATCA-30
CpG island 3
BS3 +274 to +298 BS3F 50-TTATTTTGGGTTATGGGAGTTTGTA-30 52.1 264
BS3 +538 to +513 BS3B 50-TAACCCCCTAAATCACCTTAATCTT-30
TS, transcription start site; Tan, annealing temperature; nt, nucleotides; wt, wild-type non-modified DNA; BS, bisulfite.
BS primers bind to modified DNA avoiding CpG dinucleotides. M and U primers, respectively, bind preferentially to unmethylated and methylated DNA
BS-modified and -amplified DNA: F and B, forward and backward primers, respectively. See Figure 4a for schematic representation of primer locations.
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